Cargando…

ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer

Detalles Bibliográficos
Autores principales:	Mei, Ying, Hang, Qinglei, Teng, Hongqi, Yao, Fan, Chen, Mei-Kuang, Hung, Mien-Chie, Sun, Yutong, Ma, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chongqing Medical University 2022
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363626/ https://www.ncbi.nlm.nih.gov/pubmed/37492703 http://dx.doi.org/10.1016/j.gendis.2022.09.013

Ejemplares similares

Targeting circular RNA-ZRANB1 for therapeutic intervention in retinal neurodegeneration
por: Wang, Jia-Jian, et al.
Publicado: (2018)

Deubiquitinase USP2 stabilizes the MRE11–RAD50–NBS1 complex at DNA double-strand break sites by counteracting the ubiquitination of NBS1
por: Kim, Hyunsup, et al.
Publicado: (2022)

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
por: Chu, Yu-Yi, et al.
Publicado: (2022)

Survivin as a Radioresistance Factor in Pancreatic Cancer
por: Asanuma, Koichi, et al.
Publicado: (2000)

Intron Retention and TE Exonization Events in ZRANB2
por: Park, Sang-Je, et al.
Publicado: (2012)

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
por: Jiang, Ruixin, et al.
Publicado: (2022)

Structural insights into the function of ZRANB3 in replication stress response
por: Sebesta, Marek, et al.
Publicado: (2017)

Transient HSP90 inhibition enhances the sensitivity of mantle cell lymphoma to poly (ADP-ribose) polymerase (PARP) inhibitors
por: Shi, Chaowen, et al.
Publicado: (2023)

Non-canonical function of DGCR8 in DNA double-strand break repair signaling and tumor radioresistance
por: Hang, Qinglei, et al.
Publicado: (2021)

ZRANB2/SNHG20/FOXK1 Axis regulates Vasculogenic mimicry formation in glioma
por: Li, Xiaozhi, et al.
Publicado: (2019)

CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells
por: Mintz, Rachel L., et al.
Publicado: (2020)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Effect of an alkyl spacer on the morphology and internalization of MUC1 aptamer‐naphthalimide amphiphiles for targeting and imaging triple negative breast cancer cells
por: Kuang, Huihui, et al.
Publicado: (2020)

HLA-DQB1-AS1 Promotes Cell Proliferation, Inhibits Apoptosis, and Binds with ZRANB2 Protein in Hepatocellular Carcinoma
por: Long, Jianwu, et al.
Publicado: (2022)

Strand annealing and motor driven activities of SMARCAL1 and ZRANB3 are stimulated by RAD51 and the paralog complex
por: Halder, Swagata, et al.
Publicado: (2022)

RFWD3 promotes ZRANB3 recruitment to regulate the remodeling of stalled replication forks
por: Moore, Chandler E., et al.
Publicado: (2023)

Stabilization of MYC G-quadruplex DNA by ruthenium (II) complex overcomes imatinib resistance in chronic myeloid leukemia cells harboring T315I mutation
por: Sun, Yuening, et al.
Publicado: (2022)

ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1
por: Zhang, Peijing, et al.
Publicado: (2014)

Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?
por: Wang, Hui, et al.
Publicado: (2019)

Platinum nanoparticles: an exquisite tool to overcome radioresistance
por: Li, Sha, et al.
Publicado: (2017)

Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance
por: Liu, Shuya, et al.
Publicado: (2020)

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
por: Du, Yi, et al.
Publicado: (2016)

Inhibition of livin overcomes radioresistance in nasopharyngeal carcinoma cells
por: Ma, Fei, et al.
Publicado: (2020)

NBS1 Heterozygosity and Cancer Risk
por: di Masi, Alessandra, et al.
Publicado: (2008)

LncRNA FAM181A-AS1 promotes gliomagenesis by sponging miR-129-5p and upregulating ZRANB2
por: Jiang, Xin, et al.
Publicado: (2020)

Inhibition of VEGFR2 overcomes venetoclax-resistance in diffuse large B-cell lymphoma cells
por: Shi, Yuanfei, et al.
Publicado: (2022)

A triple combination of treatments on moderate COVID-19
por: Bao, ChunMiao, et al.
Publicado: (2021)

ZRANB3 is an African-specific type 2 diabetes locus associated with beta-cell mass and insulin response
por: Adeyemo, Adebowale A., et al.
Publicado: (2019)

Twist1 promotes radioresistance in nasopharyngeal carcinoma
por: Zhang, Linli, et al.
Publicado: (2016)

NBS1 Mutation and prognosis of prostate cancer
por: Wokołorczyk, Dominika, et al.
Publicado: (2012)

Induction of HSPA4 and HSPA14 by NBS1 overexpression contributes to NBS1-induced in vitro metastatic and transformation activity
por: Wu, Chung-Yin, et al.
Publicado: (2011)

Replication Fork Slowing and Reversal upon DNA Damage Require PCNA Polyubiquitination and ZRANB3 DNA Translocase Activity
por: Vujanovic, Marko, et al.
Publicado: (2017)

Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats
por: Xin, Hongqi, et al.
Publicado: (2013)

Haploinsufficiency of KCNAB3 causes sudden cardiac death through delayed inactivation of Kv1.5 channel upon depolarization and induced myocardial apoptosis
por: Ji, He-Yu, et al.
Publicado: (2022)

NBS1 interacts with HP1 to ensure genome integrity
por: Bosso, Giuseppe, et al.
Publicado: (2019)

Interaction between NBS1 and the mTOR/Rictor/SIN1 Complex through Specific Domains
por: Wang, Jian-Qiu, et al.
Publicado: (2013)

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)
por: Hong, Jiaxin, et al.
Publicado: (2022)

Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations
por: Yalon, Michal, et al.
Publicado: (2016)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
por: Soung, Young-Hwa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vs67074ee9qre3v7nb1i7l7fmu